Metagenomi (NASDAQ:MGX) Stock Rating Upgraded by Wall Street Zen

Metagenomi (NASDAQ:MGX) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Other research analysts have also recently issued research reports about the company. Wells Fargo & Company cut their price objective on Metagenomi from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Chardan Capital began coverage on shares of Metagenomi in a research report on Tuesday, July 7th. They set a “buy” rating and a $5.00 target price on the stock. Finally, Weiss Ratings upgraded shares of Metagenomi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.00.

Metagenomi Stock Performance

NASDAQ MGX opened at $1.24 on Monday. The business’s 50 day moving average is $1.27 and its two-hundred day moving average is $1.43. Metagenomi has a 12-month low of $1.13 and a 12-month high of $3.95. The stock has a market capitalization of $46.69 million, a price-to-earnings ratio of -0.54 and a beta of 0.69.

Metagenomi (NASDAQ:MGX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Metagenomi had a negative net margin of 384.61% and a negative return on equity of 51.23%. The business had revenue of $1.25 million during the quarter, compared to analyst estimates of $5.90 million. Equities analysts forecast that Metagenomi will post -2.17 earnings per share for the current fiscal year.

Institutional Trading of Metagenomi

Several large investors have recently bought and sold shares of MGX. Renaissance Technologies LLC increased its holdings in Metagenomi by 276.3% during the 4th quarter. Renaissance Technologies LLC now owns 628,400 shares of the company’s stock valued at $1,018,000 after acquiring an additional 461,400 shares in the last quarter. Jane Street Group LLC raised its position in Metagenomi by 341.6% during the fourth quarter. Jane Street Group LLC now owns 433,859 shares of the company’s stock worth $703,000 after acquiring an additional 335,604 shares during the last quarter. Norges Bank purchased a new stake in shares of Metagenomi in the second quarter valued at about $373,000. Bridgeway Capital Management LLC lifted its holdings in shares of Metagenomi by 102.1% in the fourth quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock valued at $641,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Metagenomi by 1,394.4% in the third quarter. Two Sigma Investments LP now owns 207,528 shares of the company’s stock valued at $492,000 after purchasing an additional 193,641 shares during the last quarter.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.